Last reviewed · How we verify
HL-009 Liposomal Gel
HL-009 Liposomal Gel is a Small molecule drug developed by HanAll BioPharma Co., Ltd.. It is currently in Phase 2 development.
At a glance
| Generic name | HL-009 Liposomal Gel |
|---|---|
| Sponsor | HanAll BioPharma Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- HL-009 Liposomal Gel CI brief — competitive landscape report
- HL-009 Liposomal Gel updates RSS · CI watch RSS
- HanAll BioPharma Co., Ltd. portfolio CI
Frequently asked questions about HL-009 Liposomal Gel
What is HL-009 Liposomal Gel?
HL-009 Liposomal Gel is a Small molecule drug developed by HanAll BioPharma Co., Ltd..
Who makes HL-009 Liposomal Gel?
HL-009 Liposomal Gel is developed by HanAll BioPharma Co., Ltd. (see full HanAll BioPharma Co., Ltd. pipeline at /company/hanall-biopharma-co-ltd).
What development phase is HL-009 Liposomal Gel in?
HL-009 Liposomal Gel is in Phase 2.
Related
- Manufacturer: HanAll BioPharma Co., Ltd. — full pipeline
- Compare: HL-009 Liposomal Gel vs similar drugs
- Pricing: HL-009 Liposomal Gel cost, discount & access